THE LATEST

Benefit-risk in early-phase trials: why PV must move from safety oversight to strategic decision partner

As uncertainty defines early-phase clinical development, how can proactive benefit-riskassessment and pharmacovigilance protect patients without...

PharmaBoardroom Interview with Dr Toshiaki Nagafuji on the Japanese Clinical Development Landscape in 2026

"Mid-sized CROs like Linical can be suitable partners for relatively small pharmaceutical and biotech companies that are searching for flexibility...